296P Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial
Leisha A. Emens, Luciana Molinero, Sylvia Adams, Hope S. Rugo, Andreas Schneeweiß, Véronique Dièras, Hiroji Iwata, Carlos H. Barrios, M. Nechaeva, EP Winer, CL Chang, Jane Yuet Ching Hui, Peter Schmid, Sherene Loi
Topics & Concepts
AtezolizumabMedicineInternal medicineOncologyTriple-negative breast cancerPopulationSurrogate endpointBreast cancerPembrolizumabBiomarkerMetastatic breast cancerProgression-free survivalHazard ratioCancerImmunotherapyChemotherapyConfidence intervalEnvironmental healthChemistryBiochemistryCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsAdvanced Breast Cancer Therapies